3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Unknown
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Small Cell Lung Carcinoma
10
Sarcoma
8
Breast Neoplasms
8
Carcinoma, Hepatocellular
7
Lung Neoplasms
6
Stomach Neoplasms
5
Triple Negative Breast Neoplasms
4
Ovarian Neoplasms
4
Esophageal Squamous Cell Carcinoma
4
Carcinoma
4
Non-squamous Non-small Cell Lung Cancer
3
NSCLC
3
Glioma
3
Uterine Cervical Neoplasms
2
Urogenital Neoplasms
2
Thyroid Neoplasms
2
Pheochromocytoma
2
Paraganglioma
2
Neoplasms
2
Liver Neoplasms
2
Gynecological Cancer
2
Extensive Stage Small Cell Lung Cancer
2
Esophageal Neoplasms
2
Endometrial Neoplasms
2
Digestive System Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Advanced Solid Tumor
2
Squamous Non-small Cell Lung Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
Paclitaxel
16
Carboplatin
15
Bevacizumab
7
Hyperthermic Intraperitoneal Chemotherapy
5
Cisplatin
4
Taxes
3
Gemcitabine
3
Cytoreduction Surgical Procedures
3
Chemotherapy, Adjuvant
3
oregovomab
2
niraparib
2
fluzoparib
2
Topotecan
2
ST 1481
2
Neoadjuvant Therapy
2
Methods
2
Immunohistochemistry
2
Ifosfamide
2
Gene Expression Profiling
2
Filgrastim
2
Educational Status
2
Early Intervention, Educational
2
Amplified Fragment Length Polymorphism Analysis
2
rucaparib
1
pembrolizumab
1
paclitaxel poliglumex
1
olaparib
1
navicixizumab
1
mirvetuximab soravtansine
1
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Fallopian Tube Neoplasms
×
anlotinib
×
Clear all
NCT02584478
2023-11-08
AL3818
Advenchen Laboratories, LLC
Phase 3
Unknown
294 enrolled